The Fortress Biotech subsidiary company has acquired the rights to develop and commercialize dotinurad, a potentially best-in-class URAT1 inhibitor, in the USA, UK, European Union and Canada, from Fuji Yakuhin.

Dotinurad has been approved to treat gout and hyperuricemia in Japan and is currently in a Phase I clinical trial in the USA.